Rakuten Aspyrian Inc. has raised $150m in Series C venture capital to fund a Phase III clinical trial that it intends to start before the end of this year to test its laser-activated antibody conjugate in head and neck squamous cell carcinomas, and to initiate two to three additional studies for ASP-1929.
The San Diego-based firm has raised $238m to date with the enthusiastic backing of billionaire businessman Hiroshi Mikitani, who founded...